Cantor Fitzgerald Issues Negative Forecast for TNGX Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Research analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for Tango Therapeutics in a report released on Monday, March 10th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will earn ($1.48) per share for the year, down from their prior estimate of ($1.39). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share.

Tango Therapeutics Stock Performance

Shares of NASDAQ TNGX opened at $1.97 on Wednesday. The company’s fifty day moving average price is $2.67 and its 200 day moving average price is $4.84. Tango Therapeutics has a 1 year low of $1.72 and a 1 year high of $12.02. The company has a market capitalization of $212.97 million, a PE ratio of -1.67 and a beta of 0.87.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The firm had revenue of $4.12 million for the quarter, compared to analysts’ expectations of $7.84 million.

Insiders Place Their Bets

In other Tango Therapeutics news, CEO Barbara Weber sold 9,778 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $29,236.22. Following the completion of the transaction, the chief executive officer now directly owns 1,631,264 shares in the company, valued at approximately $4,877,479.36. This represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 24,268 shares of company stock worth $72,561. Company insiders own 6.30% of the company’s stock.

Hedge Funds Weigh In On Tango Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd acquired a new position in Tango Therapeutics during the fourth quarter worth $33,000. Quest Partners LLC raised its position in Tango Therapeutics by 1,448.4% during the third quarter. Quest Partners LLC now owns 10,885 shares of the company’s stock worth $84,000 after acquiring an additional 10,182 shares during the period. Stonebrook Private Inc. acquired a new position in Tango Therapeutics during the fourth quarter worth $34,000. Ameriprise Financial Inc. acquired a new position in Tango Therapeutics during the fourth quarter worth $35,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in Tango Therapeutics during the fourth quarter worth $38,000. 78.99% of the stock is currently owned by institutional investors and hedge funds.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.